These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 19191091)

  • 1. Long-term effects of rivastigmine capsules in patients with traumatic brain injury.
    Silver JM; Koumaras B; Meng X; Potkin SG; Reyes PF; Harvey PD; Katz DI; Gunay I; Arciniegas DB
    Brain Inj; 2009 Feb; 23(2):123-32. PubMed ID: 19191091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of rivastigmine on cognitive function in patients with traumatic brain injury.
    Silver JM; Koumaras B; Chen M; Mirski D; Potkin SG; Reyes P; Warden D; Harvey PD; Arciniegas D; Katz DI; Gunay I
    Neurology; 2006 Sep; 67(5):748-55. PubMed ID: 16966534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
    Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
    Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits.
    Chouinard S; Stip E; Poulin J; Melun JP; Godbout R; Guillem F; Cohen H
    Curr Med Res Opin; 2007 Mar; 23(3):575-83. PubMed ID: 17355738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
    Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
    Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive function in early clinical phase huntington disease after rivastigmine treatment.
    Sešok S; Bolle N; Kobal J; Bucik V; Vodušek DB
    Psychiatr Danub; 2014 Sep; 26(3):239-48. PubMed ID: 25191771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.
    Farlow MR; Alva G; Meng X; Olin JT
    Curr Med Res Opin; 2010 Feb; 26(2):263-9. PubMed ID: 19929593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
    Winblad B; Grossberg G; Frölich L; Farlow M; Zechner S; Nagel J; Lane R
    Neurology; 2007 Jul; 69(4 Suppl 1):S14-22. PubMed ID: 17646619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.
    Feldman HH; Ferris S; Winblad B; Sfikas N; Mancione L; He Y; Tekin S; Burns A; Cummings J; del Ser T; Inzitari D; Orgogozo JM; Sauer H; Scheltens P; Scarpini E; Herrmann N; Farlow M; Potkin S; Charles HC; Fox NC; Lane R
    Lancet Neurol; 2007 Jun; 6(6):501-12. PubMed ID: 17509485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized controlled trial of rivastigmine for chronic sequels of traumatic brain injury-what it showed and taught?
    Tenovuo O; Alin J; Helenius H
    Brain Inj; 2009 Jun; 23(6):548-58. PubMed ID: 19484628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease.
    Narasimhalu K; Effendy S; Sim CH; Lee JM; Chen I; Hia SB; Xue HL; Corrales MP; Chang HM; Wong MC; Chen CP; Tan EK
    Acta Neurol Scand; 2010 Apr; 121(4):217-24. PubMed ID: 19951274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study.
    Ballard C; Sauter M; Scheltens P; He Y; Barkhof F; van Straaten EC; van der Flier WM; Hsu C; Wu S; Lane R
    Curr Med Res Opin; 2008 Sep; 24(9):2561-74. PubMed ID: 18674411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of body weight on tolerability of rivastigmine transdermal patch: a post-hoc analysis of a double-blind trial in patients with Alzheimer disease.
    Lee JH; Sevigny J
    Alzheimer Dis Assoc Disord; 2011; 25(1):58-62. PubMed ID: 20975519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivastigmine for cognitive impairment after spontaneous subarachnoid haemorrhage: a pilot study.
    Wong GK; Wong R; Mok V; Wong A; Fan D; Leung G; Chan A; Poon WS
    J Clin Pharm Ther; 2009 Dec; 34(6):657-63. PubMed ID: 20175798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients.
    Visser PJ; Scheltens P; Pelgrim E; Verhey FR;
    Dement Geriatr Cogn Disord; 2005; 19(2-3):126-33. PubMed ID: 15627759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study.
    Choi SH; Park KW; Na DL; Han HJ; Kim EJ; Shim YS; Lee JH;
    Curr Med Res Opin; 2011 Jul; 27(7):1375-83. PubMed ID: 21561398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot study.
    Simioni S; Cavassini M; Annoni JM; Métral M; Iglesias K; Rimbault Abraham A; Jilek S; Calmy A; Müller H; Fayet-Mello A; Giacobini E; Hirschel B; Du Pasquier RA
    Neurology; 2013 Feb; 80(6):553-60. PubMed ID: 23345635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.
    Poewe W; Wolters E; Emre M; Onofrj M; Hsu C; Tekin S; Lane R;
    Mov Disord; 2006 Apr; 21(4):456-61. PubMed ID: 16229010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.
    Winblad B; Cummings J; Andreasen N; Grossberg G; Onofrj M; Sadowsky C; Zechner S; Nagel J; Lane R
    Int J Geriatr Psychiatry; 2007 May; 22(5):456-67. PubMed ID: 17380489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial.
    Ballard C; Margallo-Lana M; Juszczak E; Douglas S; Swann A; Thomas A; O'Brien J; Everratt A; Sadler S; Maddison C; Lee L; Bannister C; Elvish R; Jacoby R
    BMJ; 2005 Apr; 330(7496):874. PubMed ID: 15722369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.